| Year |
Citation |
Score |
| 2021 |
Marsillach J, Richter RJ, Costa LG, Furlong CE. Paraoxonase-1 (PON1) Status Analysis Using Non-Organophosphate Substrates. Current Protocols. 1: e25. PMID 33484495 DOI: 10.1002/cpz1.25 |
0.341 |
|
| 2017 |
Costa LG, Cole TB, Garrick JM, Marsillach J, Furlong CE. Metals and Paraoxonases. Advances in Neurobiology. 18: 85-111. PMID 28889264 DOI: 10.1007/978-3-319-60189-2_5 |
0.384 |
|
| 2016 |
Souza-Nogueira A, Camargo AE, Remondi FA, Paoliello MM, Richter RJ, Furlong CE, Barbosa DS, Maes M, Moreira EG. Paraoxonase 1 (PON1) Q192R genotypes and their interaction with smoking strongly increase atherogenicity and the Framingham risk score. Archives of Endocrinology and Metabolism. 60: 426-435. PMID 27812605 DOI: 10.1590/2359-3997000000184 |
0.326 |
|
| 2016 |
Marsillach J, Costa LG, Furlong CE. Paraoxonase-1 and Early-Life Environmental Exposures. Annals of Global Health. 82: 100-10. PMID 27325068 DOI: 10.1016/J.Aogh.2016.01.009 |
0.374 |
|
| 2016 |
Furlong CE, Marsillach J, Jarvik GP, Costa LG. Paraoxonases-1, -2 and -3: What are their functions? Chemico-Biological Interactions. PMID 27238723 DOI: 10.1016/J.Cbi.2016.05.036 |
0.341 |
|
| 2015 |
Kim DS, Burt AA, Ranchalis JE, Vuletic S, Vaisar T, Li WF, Rosenthal EA, Dong W, Eintracht JF, Motulsky AG, Brunzell JD, Albers JJ, Furlong CE, Jarvik GP. PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. Journal of Lipid Research. 56: 1351-62. PMID 26009633 DOI: 10.1194/Jlr.P058032 |
0.35 |
|
| 2014 |
Marsillach J, Suzuki SM, Richter RJ, McDonald MG, Rademacher PM, MacCoss MJ, Hsieh EJ, Rettie AE, Furlong CE. Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase. Plos One. 9: e110054. PMID 25333274 DOI: 10.1371/Journal.Pone.0110054 |
0.764 |
|
| 2014 |
Cole TB, Li WF, Co AL, Hay AM, MacDonald JW, Bammler TK, Farin FM, Costa LG, Furlong CE. Repeated gestational exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1) modulated effects in maternal and fetal tissues. Toxicological Sciences : An Official Journal of the Society of Toxicology. 141: 409-22. PMID 25070982 DOI: 10.1093/Toxsci/Kfu144 |
0.376 |
|
| 2014 |
Kim DS, Crosslin DR, Auer PL, Suzuki SM, Marsillach J, Burt AA, Gordon AS, Meschia JF, Nalls MA, Worrall BB, Longstreth WT, Gottesman RF, Furlong CE, Peters U, Rich SS, et al. Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project. Journal of Lipid Research. 55: 1173-1178. PMID 24711634 DOI: 10.1194/Jlr.P049247 |
0.732 |
|
| 2014 |
Costa LG, de Laat R, Dao K, Pellacani C, Cole TB, Furlong CE. Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection. Neurotoxicology. 43: 3-9. PMID 24012887 DOI: 10.1016/J.Neuro.2013.08.011 |
0.306 |
|
| 2014 |
Marsillach J, Hsieh E, R.J. R, Maccoss M, Hoofnagle A, Furlong C. Use of dried blood spots and mass spectrometry for biomonitoring organophosphorus exposures Neurotoxicology and Teratology. 43: 92. DOI: 10.1016/J.Ntt.2014.04.052 |
0.312 |
|
| 2014 |
Furlong C, Li W, Cole T, Beyer R, Bammler T, S.S. P, Farin F, Costa L. Effects of paraoxonase-1 (PON1) status on pre- and postnatal exposures to chlorpyrifos oxon and diazoxon Neurotoxicology and Teratology. 43: 85-86. DOI: 10.1016/J.Ntt.2014.04.033 |
0.333 |
|
| 2013 |
Kim DS, Maden SK, Burt AA, Ranchalis JE, Furlong CE, Jarvik GP. Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids in Health and Disease. 12: 183. PMID 24330840 DOI: 10.1186/1476-511X-12-183 |
0.302 |
|
| 2013 |
Kim DS, Marsillach J, Furlong CE, Jarvik GP. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics. 14: 1495-515. PMID 24024900 DOI: 10.2217/Pgs.13.147 |
0.374 |
|
| 2013 |
Costa LG, Tait L, de Laat R, Dao K, Giordano G, Pellacani C, Cole TB, Furlong CE. Modulation of paraoxonase 2 (PON2) in mouse brain by the polyphenol quercetin: a mechanism of neuroprotection? Neurochemical Research. 38: 1809-18. PMID 23743621 DOI: 10.1007/S11064-013-1085-1 |
0.329 |
|
| 2013 |
Kim DS, Burt AA, Ranchalis JE, Jarvik ER, Rosenthal EA, Hatsukami TS, Furlong CE, Jarvik GP. Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. Journal of Lipid Research. 54: 1512-20. PMID 23482652 DOI: 10.1194/Jlr.P035238 |
0.311 |
|
| 2013 |
Marsillach J, Costa LG, Furlong CE. Protein adducts as biomarkers of exposure to organophosphorus compounds. Toxicology. 307: 46-54. PMID 23261756 DOI: 10.1016/J.Tox.2012.12.007 |
0.438 |
|
| 2013 |
Kim DS, Burt AA, Crosslin DR, Robertson PD, Ranchalis JE, Boyko EJ, Nickerson DA, Furlong CE, Jarvik GP. Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. Journal of Lipid Research. 54: 552-60. PMID 23160181 DOI: 10.1194/Jlr.P033266 |
0.323 |
|
| 2013 |
Marsillach J, Hsieh EJ, Richter RJ, MacCoss MJ, Furlong CE. Proteomic analysis of adducted butyrylcholinesterase for biomonitoring organophosphorus exposures. Chemico-Biological Interactions. 203: 85-90. PMID 23123252 DOI: 10.1016/J.Cbi.2012.10.019 |
0.419 |
|
| 2013 |
Baker PE, Cole TB, Cartwright M, Suzuki SM, Thummel KE, Lin YS, Co AL, Rettie AE, Kim JH, Furlong CE. Identifying safer anti-wear triaryl phosphate additives for jet engine lubricants. Chemico-Biological Interactions. 203: 257-64. PMID 23085349 DOI: 10.1016/J.Cbi.2012.10.005 |
0.765 |
|
| 2013 |
Costa LG, Giordano G, Cole TB, Marsillach J, Furlong CE. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology. 307: 115-22. PMID 22884923 DOI: 10.1016/J.Tox.2012.07.011 |
0.436 |
|
| 2012 |
Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Nakayama KS, Jarvik ER, Eintracht JF, Rosenthal EA, Furlong CE, Jarvik GP. Dietary cholesterol increases paraoxonase 1 enzyme activity. Journal of Lipid Research. 53: 2450-8. PMID 22896672 DOI: 10.1194/Jlr.P030601 |
0.313 |
|
| 2012 |
Cole TB, Fisher JC, Burbacher TM, Costa LG, Furlong CE. Neurobehavioral assessment of mice following repeated postnatal exposure to chlorpyrifos-oxon. Neurotoxicology and Teratology. 34: 311-22. PMID 22425525 DOI: 10.1016/J.Ntt.2012.02.003 |
0.405 |
|
| 2011 |
Furlong CE. Exposure to triaryl phosphates: metabolism and biomarkers of exposure. Journal of Biological Physics and Chemistry : Jbpc. 11. PMID 24285929 DOI: 10.4024/28Fu11A.Jbpc.11.04 |
0.365 |
|
| 2011 |
Marsillach J, Richter RJ, Kim JH, Stevens RC, MacCoss MJ, Tomazela D, Suzuki SM, Schopfer LM, Lockridge O, Furlong CE. Biomarkers of organophosphorus (OP) exposures in humans. Neurotoxicology. 32: 656-60. PMID 21767566 DOI: 10.1016/J.Neuro.2011.06.005 |
0.77 |
|
| 2011 |
Liyasova M, Li B, Schopfer LM, Nachon F, Masson P, Furlong CE, Lockridge O. Exposure to tri-o-cresyl phosphate detected in jet airplane passengers. Toxicology and Applied Pharmacology. 256: 337-47. PMID 21723309 DOI: 10.1016/J.Taap.2011.06.016 |
0.364 |
|
| 2011 |
Cole TB, Beyer RP, Bammler TK, Park SS, Farin FM, Costa LG, Furlong CE. Repeated developmental exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1)-modulated effects on cerebellar gene expression. Toxicological Sciences : An Official Journal of the Society of Toxicology. 123: 155-69. PMID 21673326 DOI: 10.1093/Toxsci/Kfr157 |
0.375 |
|
| 2011 |
Giordano G, Cole TB, Furlong CE, Costa LG. Paraoxonase 2 (PON2) in the mouse central nervous system: a neuroprotective role? Toxicology and Applied Pharmacology. 256: 369-78. PMID 21354197 DOI: 10.1016/J.Taap.2011.02.014 |
0.308 |
|
| 2011 |
Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochemical Pharmacology. 81: 337-44. PMID 21093416 DOI: 10.1016/J.Bcp.2010.11.008 |
0.397 |
|
| 2010 |
Schopfer LM, Furlong CE, Lockridge O. Development of diagnostics in the search for an explanation of aerotoxic syndrome. Analytical Biochemistry. 404: 64-74. PMID 20447373 DOI: 10.1016/J.Ab.2010.04.032 |
0.33 |
|
| 2010 |
Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP. Human PON1, a biomarker of risk of disease and exposure. Chemico-Biological Interactions. 187: 355-61. PMID 20338154 DOI: 10.1016/J.Cbi.2010.03.033 |
0.792 |
|
| 2010 |
Mackenzie Ross SJ, Brewin CR, Curran HV, Furlong CE, Abraham-Smith KM, Harrison V. Neuropsychological and psychiatric functioning in sheep farmers exposed to low levels of organophosphate pesticides. Neurotoxicology and Teratology. 32: 452-9. PMID 20227490 DOI: 10.1016/J.Ntt.2010.03.004 |
0.309 |
|
| 2010 |
Kim JH, Stevens RC, MacCoss MJ, Goodlett DR, Scherl A, Richter RJ, Suzuki SM, Furlong CE. Identification and characterization of biomarkers of organophosphorus exposures in humans. Advances in Experimental Medicine and Biology. 660: 61-71. PMID 20221871 DOI: 10.1007/978-1-60761-350-3_7 |
0.769 |
|
| 2010 |
Cole TB, Jansen K, Park S, Li WF, Furlong CE, Costa LG. The toxicity of mixtures of specific organophosphate compounds is modulated by paraoxonase 1 status. Advances in Experimental Medicine and Biology. 660: 47-60. PMID 20221870 DOI: 10.1007/978-1-60761-350-3_6 |
0.397 |
|
| 2010 |
Suzuki SM, Stevens RC, Richter RJ, Cole TB, Park S, Otto TC, Cerasoli DM, Lenz DE, Furlong CE. Engineering human PON1 in an E. coli expression system. Advances in Experimental Medicine and Biology. 660: 37-45. PMID 20221869 DOI: 10.1007/978-1-60761-350-3_5 |
0.762 |
|
| 2010 |
Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 status as a risk factor for disease or exposure. Advances in Experimental Medicine and Biology. 660: 29-35. PMID 20221868 DOI: 10.1007/978-1-60761-350-3_4 |
0.436 |
|
| 2010 |
Hofmann JN, Keifer MC, Checkoway H, De Roos AJ, Farin FM, Fenske RA, Richter RJ, van Belle G, Furlong CE. Biomarkers of sensitivity and exposure in Washington state pesticide handlers. Advances in Experimental Medicine and Biology. 660: 19-27. PMID 20221867 DOI: 10.1007/978-1-60761-350-3_3 |
0.393 |
|
| 2010 |
Hofmann JN, Keifer MC, De Roos AJ, Fenske RA, Furlong CE, van Belle G, Checkoway H. Occupational determinants of serum cholinesterase inhibition among organophosphate-exposed agricultural pesticide handlers in Washington State. Occupational and Environmental Medicine. 67: 375-86. PMID 19819864 DOI: 10.1136/Oem.2009.046391 |
0.319 |
|
| 2009 |
Hofmann JN, Keifer MC, Furlong CE, De Roos AJ, Farin FM, Fenske RA, van Belle G, Checkoway H. Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. Environmental Health Perspectives. 117: 1402-8. PMID 19750105 DOI: 10.1289/Ehp.0900682 |
0.413 |
|
| 2009 |
Jansen KL, Cole TB, Park SS, Furlong CE, Costa LG. Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicology and Applied Pharmacology. 236: 142-53. PMID 19371602 DOI: 10.1016/J.Taap.2009.02.001 |
0.359 |
|
| 2009 |
Huen K, Richter R, Furlong C, Eskenazi B, Holland N. Validation of PON1 enzyme activity assays for longitudinal studies. Clinica Chimica Acta; International Journal of Clinical Chemistry. 402: 67-74. PMID 19146843 DOI: 10.1016/J.Cca.2008.12.019 |
0.308 |
|
| 2009 |
Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicology and Applied Pharmacology. 235: 1-9. PMID 19071155 DOI: 10.1016/J.Taap.2008.11.001 |
0.412 |
|
| 2008 |
Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circulation. Cardiovascular Genetics. 1: 147-52. PMID 20031556 DOI: 10.1161/Circgenetics.108.811638 |
0.411 |
|
| 2008 |
Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proceedings of the National Academy of Sciences of the United States of America. 105: 12780-4. PMID 18711144 DOI: 10.1073/Pnas.0805865105 |
0.776 |
|
| 2007 |
Furlong CE. Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. Journal of Biochemical and Molecular Toxicology. 21: 197-205. PMID 17936934 DOI: 10.1002/Jbt.20181 |
0.396 |
|
| 2006 |
Holland N, Furlong C, Bastaki M, Richter R, Bradman A, Huen K, Beckman K, Eskenazi B. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environmental Health Perspectives. 114: 985-91. PMID 16835048 DOI: 10.1289/Ehp.8540 |
0.332 |
|
| 2006 |
Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenetics and Genomics. 16: 183-90. PMID 16495777 DOI: 10.1097/01.Fpc.0000189796.21770.D3 |
0.336 |
|
| 2006 |
Carlson CS, Heagerty PJ, Hatsukami TS, Richter RJ, Ranchalis J, Lewis J, Bacus TJ, McKinstry LA, Schellenberg GD, Rieder M, Nickerson D, Furlong CE, Chait A, Jarvik GP. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. Journal of Lipid Research. 47: 1014-24. PMID 16474172 DOI: 10.1194/Jlr.M500517-Jlr200 |
0.342 |
|
| 2006 |
Costa LG, Cole TB, Furlong CE. Gene-environment interactions: Paraoxonase (PON1) and sensitivity to organophosphate toxicity Laboratory Medicine. 37: 109-113. DOI: 10.1309/020Xq8Hqjjttjdk4 |
0.405 |
|
| 2005 |
Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward AD, Lusis AJ, Costa LG. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology. 26: 651-9. PMID 16112327 DOI: 10.1016/J.Neuro.2004.08.002 |
0.386 |
|
| 2005 |
Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenetics and Genomics. 15: 589-98. PMID 16007003 DOI: 10.1097/01.Fpc.0000167327.08034.D2 |
0.351 |
|
| 2005 |
Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA, Gortner DA, Boyko E, Schellenberg GD, Furlong CE, Jarvik GP. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. Journal of Lipid Research. 46: 1888-95. PMID 15995178 DOI: 10.1194/Jlr.M400489-Jlr200 |
0.306 |
|
| 2005 |
Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. Paraoxonase 1 (PON1) status and risk of insecticide exposure. Journal of Biochemical and Molecular Toxicology. 19: 182-3. PMID 15977192 DOI: 10.1002/Jbt.20079 |
0.408 |
|
| 2005 |
Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology. 69: 541-50. PMID 15670573 DOI: 10.1016/J.Bcp.2004.08.027 |
0.38 |
|
| 2005 |
Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clinica Chimica Acta; International Journal of Clinical Chemistry. 352: 37-47. PMID 15653099 DOI: 10.1016/J.Cccn.2004.09.019 |
0.42 |
|
| 2004 |
Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE. Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. Current Protocols in Toxicology / Editorial Board, Mahin D. Maines (Editor-in-Chief) ... [Et Al.]. Unit4.12. PMID 20945303 DOI: 10.1002/0471140856.Tx0412S19 |
0.338 |
|
| 2004 |
Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, Barr DB, Furlong CE, Holland NT. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environmental Health Perspectives. 112: 1116-24. PMID 15238287 DOI: 10.1289/Ehp.6789 |
0.334 |
|
| 2003 |
Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. Expression of human paraoxonase (PON1) during development. Pharmacogenetics. 13: 357-64. PMID 12777966 DOI: 10.1097/00008571-200306000-00007 |
0.362 |
|
| 2003 |
Jarvik GP, Jampsa R, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA, Furlong CE. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status Pharmacogenetics. 13: 291-295. PMID 12724622 DOI: 10.1097/00008571-200305000-00009 |
0.31 |
|
| 2003 |
Costa LG, Cole TB, Furlong CE. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. Journal of Toxicology. Clinical Toxicology. 41: 37-45. PMID 12645966 DOI: 10.1081/Clt-120018269 |
0.414 |
|
| 2003 |
Kelada SN, Costa-Mallen P, Checkoway H, Viernes HA, Farin FM, Smith-Weller T, Franklin GM, Costa LG, Longstreth WT, Furlong CE, Jarvik GP, Swanson PD. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 74: 546-7. PMID 12640090 DOI: 10.1136/Jnnp.74.4.546 |
0.376 |
|
| 2003 |
Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annual Review of Medicine. 54: 371-92. PMID 12525679 DOI: 10.1146/Annurev.Med.54.101601.152421 |
0.323 |
|
| 2003 |
Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, Furlong CE. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals. 8: 1-12. PMID 12519632 DOI: 10.1080/13547500210148315 |
0.418 |
|
| 2002 |
Furlong CE, Cole TB, Jarvik GP, Costa LG. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics. 3: 341-8. PMID 12052142 DOI: 10.1517/14622416.3.3.341 |
0.371 |
|
| 2002 |
Furlong CE, Li W, Shih DM, Lusis AJ, Richter RJ, Costa LG. Genetic Factors in Susceptibility: Serum PON1 Variation Between Individuals and Species Human and Ecological Risk Assessment: An International Journal. 8: 31-43. DOI: 10.1080/20028091056700 |
0.386 |
|
| 2001 |
Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. American Journal of Human Genetics. 68: 1428-1436. PMID 11335891 DOI: 10.1086/320600 |
0.349 |
|
| 2001 |
Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 11: 77-84. PMID 11207034 DOI: 10.1097/00008571-200102000-00009 |
0.35 |
|
| 2001 |
Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics. 10: 767-79. PMID 11191881 DOI: 10.1097/00008571-200012000-00002 |
0.381 |
|
| 2000 |
Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arteriosclerosis, Thrombosis, and Vascular Biology. 20: 2441-7. PMID 11073850 DOI: 10.1161/01.Atv.20.11.2441 |
0.311 |
|
| 2000 |
Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics. 10: 453-60. PMID 10898114 DOI: 10.1097/00008571-200007000-00008 |
0.376 |
|
| 1999 |
Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chemico-Biological Interactions. 429-38. PMID 10421480 DOI: 10.1016/S0009-2797(99)00055-1 |
0.433 |
|
| 1999 |
Hulla JE, Miller MS, Taylor JA, Hein DW, Furlong CE, Omiecinski CJ, Kunkel TA. Symposium overview: The role of genetic polymorphism and repair deficiencies in environmental disease Toxicological Sciences. 47: 135-143. PMID 10220849 DOI: 10.1093/Toxsci/47.2.135 |
0.369 |
|
| 1999 |
Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 9: 745-753. DOI: 10.1097/00008571-199912000-00009 |
0.37 |
|
| 1998 |
Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature. 394: 284-287. PMID 9685159 DOI: 10.1038/28406 |
0.317 |
|
| 1997 |
Li WF, Matthews C, Disteche CM, Costa LG, Furlong CE. Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. Pharmacogenetics. 7: 137-44. PMID 9170151 DOI: 10.1097/00008571-199704000-00007 |
0.329 |
|
| 1997 |
Yuknavage KL, Fenske RA, Kalman DA, Keifer MC, Furlong CE. Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. Journal of Toxicology and Environmental Health. 51: 35-55. PMID 9169060 DOI: 10.1080/00984109708984010 |
0.325 |
|
| 1996 |
Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genetics. 14: 334-6. PMID 8896566 DOI: 10.1038/Ng1196-334 |
0.419 |
|
| 1996 |
Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, Brunzell JD. Paraoxonase Genotypes, Lipoprotein Lipase Activity, and HDL Arteriosclerosis, Thrombosis, and Vascular Biology. 16: 1243-1249. PMID 8857920 DOI: 10.1161/01.Atv.16.10.1243 |
0.355 |
|
| 1996 |
Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE. Structural organization of the human PON1 gene. Genomics. 35: 586-9. PMID 8812495 DOI: 10.1006/Geno.1996.0401 |
0.375 |
|
| 1995 |
Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicology Letters. 76: 219-26. PMID 7539166 DOI: 10.1016/0378-4274(95)80006-Y |
0.382 |
|
| 1994 |
Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JAK. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33: 832-839. PMID 8292612 DOI: 10.1021/Bi00169A026 |
0.362 |
|
| 1994 |
Sopher BL, Fukuchi Ki, Smith AC, Leppig KA, Furlong CE, Martin GM. Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the β-amyloid precursor protein Molecular Brain Research. 26: 207-217. PMID 7854049 DOI: 10.1016/0169-328X(94)90092-2 |
0.307 |
|
| 1993 |
Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics. 3: 73-6. PMID 8098250 DOI: 10.1038/Ng0193-73 |
0.361 |
|
| 1993 |
Li WF, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. Journal of Toxicology and Environmental Health. 40: 337-46. PMID 7693961 DOI: 10.1080/15287399309531798 |
0.396 |
|
| 1991 |
Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 30: 10141-9. PMID 1657140 DOI: 10.1021/Bi00106A010 |
0.301 |
|
| 1990 |
Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicology and Applied Pharmacology. 103: 66-76. PMID 1690462 DOI: 10.1016/0041-008X(90)90263-T |
0.323 |
|
| 1989 |
Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Analytical Biochemistry. 180: 242-7. PMID 2479288 DOI: 10.1016/0003-2697(89)90424-7 |
0.386 |
|
| 1982 |
Schellenberg GD, Wilson NM, Copeland BR, Furlong CE. Transketolase from human red blood cells. Methods in Enzymology. 90: 223-8. PMID 7154948 DOI: 10.1016/S0076-6879(82)90129-X |
0.312 |
|
| Show low-probability matches. |